Core Insights - Alumis Inc. has completed patient enrollment in pivotal clinical trials for its investigational therapy envudeucitinib, with topline data expected in early Q1 2026 for plaque psoriasis and Q3 2026 for systemic lupus erythematosus [1][2][5] - The company has successfully merged with ACELYRIN, Inc., enhancing its financial position and supporting the advancement of its late-stage immunology pipeline [1][2][7] - As of June 30, 2025, Alumis reported cash, cash equivalents, and marketable securities totaling $486.3 million, which is expected to fund operations into 2027 [1][10] Clinical Development - The Phase 3 ONWARD program for envudeucitinib includes two parallel global trials designed to evaluate its efficacy and safety in adult patients with moderate-to-severe plaque psoriasis, with topline data expected in early Q1 2026 [5][8] - The Phase 2b LUMUS trial for systemic lupus erythematosus has enrolled 408 patients, with topline data anticipated in Q3 2026 [5][8] Financial Performance - For the quarter ended June 30, 2025, Alumis reported total revenue of $2.7 million, primarily from collaboration revenue, compared to no revenue in the same quarter of 2024 [7][15] - Research and development expenses increased to $108.8 million for Q2 2025, up from $48.6 million in Q2 2024, driven by clinical trial costs and merger-related expenses [7][15] - The company recorded a net income of $59.3 million for Q2 2025, including a non-operating gain of $187.9 million from the merger with ACELYRIN, compared to a net loss of $56.5 million in Q2 2024 [7][15] Corporate Developments - The merger with ACELYRIN has strengthened Alumis' balance sheet, allowing for the advancement of its late-stage pipeline through multiple planned key data readouts [6][9] - The company has appointed Sanam Pangali as Chief Legal Officer and Corporate Secretary, bringing nearly two decades of legal expertise [6][8] Pipeline Updates - Alumis is advancing A-005, a fully CNS-penetrant TYK2 inhibitor, towards Phase 2 clinical trials for multiple sclerosis, expected to initiate in the first half of 2026 [8] - The company is also developing lonigutamab, a next-generation therapy for thyroid eye disease, which has received Fast Track Designation from the FDA [8][11]

Core Insights - Alumis Inc. has completed patient enrollment in its global LUMUS Phase 2b trial for ESK-001, a next-generation oral TYK2 inhibitor targeting systemic lupus erythematosus (SLE), with topline data expected in Q3 2026 [1][5]. Company Overview - Alumis is a late-stage biopharma company focused on developing targeted therapies for immune-mediated diseases, leveraging a proprietary data analytics platform [7]. - The company is developing a pipeline of oral TYK2 inhibitors, including ESK-001 for SLE and moderate-to-severe plaque psoriasis, and A-005 for neuroinflammatory and neurodegenerative diseases [7]. Clinical Trial Details - The LUMUS Phase 2b trial is a randomized, double-blind, placebo-controlled study involving 408 patients with moderately-to-severely active, autoantibody-positive SLE, assessing the efficacy of ESK-001 over 48 weeks [2][5]. - The primary endpoint of the trial is to evaluate improvements in overall disease activity using the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) at Week 48 [2][5]. Drug Mechanism and Efficacy - ESK-001 is designed to selectively target key inflammatory drivers, such as type 1 interferon (IFN), aiming for maximal inhibition while minimizing off-target effects [3][4]. - Clinical data from the psoriasis program indicates that ESK-001 downregulates key cytokines and disease biomarkers, suggesting potential to reduce SLE disease activity [4]. Future Prospects - The company anticipates that ESK-001 could provide biologic-like clinical responses for SLE, based on its performance in previous clinical studies [4].

Core Insights - Alumis Inc. has completed patient enrollment in its global LUMUS Phase 2b trial for ESK-001, a next-generation oral TYK2 inhibitor aimed at treating systemic lupus erythematosus (SLE) [2][3] - The trial enrolled 408 patients and topline data is expected in Q3 2026, marking a significant milestone for both the company and the lupus community [3][6] - ESK-001 is designed to selectively target key inflammatory drivers, potentially offering a new treatment option for patients with SLE who currently have limited choices [3][4] Company Overview - Alumis is a late-stage biopharma company focused on developing targeted therapies for immune-mediated diseases, leveraging a proprietary data analytics platform [8] - The company's pipeline includes ESK-001 for SLE and moderate-to-severe plaque psoriasis, as well as A-005 for neuroinflammatory and neurodegenerative diseases [8] - Alumis aims to improve patient health outcomes through its innovative therapies and precision approach [8] Clinical Trial Details - The LUMUS Phase 2b trial is a randomized, double-blind, placebo-controlled study evaluating multiple doses of ESK-001 over 48 weeks [6] - The primary endpoint is to assess improvements in overall disease activity using the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) at Week 48 [3][6] - Following the trial, eligible patients may participate in an open-label extension or a four-week safety follow-up [3] ESK-001 Mechanism and Previous Data - ESK-001 is a highly selective TYK2 inhibitor that targets proinflammatory mediators, aiming for maximal inhibition with minimal off-target effects [4][5] - Clinical data from Alumis' psoriasis program indicates that ESK-001 effectively downregulates key cytokines and disease biomarkers, suggesting potential efficacy in reducing SLE disease activity [5] - Phase 1 studies showed that ESK-001 achieved full, sustained target inhibition and was well tolerated in healthy volunteers [5]

Core Insights - Alumis Inc. has promoted Sanam Pangali to Chief Legal Officer and Corporate Secretary, succeeding Sara Klein who has retired [1][2] - Sanam Pangali has a strong background in legal and business roles, previously serving as Senior Vice President, Legal at Alumis and holding leadership positions at ACELYRIN, Inc. and other biopharmaceutical companies [2] - Alumis is focused on developing next-generation targeted therapies for immune-mediated diseases, with a pipeline that includes oral tyrosine kinase 2 inhibitors and anti-insulin-like growth factor 1 receptor therapy [3] Company Overview - Alumis is a late-stage biopharma company dedicated to improving patient health outcomes in immune-mediated diseases [3] - The company utilizes a proprietary data analytics platform to develop its therapies, which include ESK-001 for systemic immune-mediated disorders and A-005 for neuroinflammatory diseases [3] - The pipeline also features lonigutamab for thyroid eye disease and several preclinical programs identified through a precision approach [3]

Summary of Illumis (ALMS) Conference Call Company Overview - Illumis recently completed a merger with Accelerin to strengthen its position as a leading immunology company [2][3] - The merger aims to combine their pipelines and financial resources to build a well-capitalized precision immunology company [3] Key Pipeline Developments - Upcoming key readouts include: - Psoriasis readout expected in early 2026 after completing enrollment of over 1,700 patients in a Phase III trial [4][7] - Lupus readout planned for next year, with ongoing Phase II trial expected to complete enrollment by summer [5][8] - The company has a cash runway into 2027, with approximately $600 million in cash and 100 million shares outstanding [6] Psoriasis Program - The psoriasis program is in Phase III, with a six-month readout expected early in 2026 [4][7] - The trial has been completed ahead of schedule, indicating strong patient interest [7] - The company is focused on maximizing target inhibition with its TYK2 inhibitors, which have shown promising results in clinical trials [12][21] Lupus Program - The lupus program is designed as a pivotal trial to demonstrate significant efficacy over placebo [43] - The company aims to reduce the placebo effect by ensuring strict patient selection and monitoring [44] - The ongoing study is expected to read out in 2026, with a focus on genetic validation for TYK2 inhibition in lupus patients [38][40] Competitive Landscape - The psoriasis market is competitive, but injectable biologics account for less than 10% of treatments, indicating a significant opportunity for effective oral therapies [34][35] - The company aims to capture a portion of the market by offering a highly efficacious and safe oral drug [34] Differentiation and Safety Profile - Illumis emphasizes the importance of maximum target inhibition for efficacy and safety, with ongoing studies supporting this hypothesis [20][21] - The safety profile of their drugs has been favorable, with no significant safety findings reported to date [24][25] Future Milestones - The company plans to initiate a Phase II trial for its brain-penetrant TYK2 inhibitor, A5, later this year [52][56] - A once-a-day formulation for ESK001 is also in development, with plans to announce details later this year [57] - Key readouts for psoriasis and lupus are anticipated in 2026, along with potential updates on MS and lanagutamab [58] External Validation - A partnership with Kakken in Japan for the development of ESK001 has provided external validation and a significant financial boost [46] Conclusion - Illumis is strategically positioned in the immunology space with a robust pipeline and a focus on maximizing efficacy and safety through innovative drug development and strategic partnerships [2][3][34]

Company Overview - Alumis Inc. is a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases [3] - The company utilizes a proprietary data analytics platform and precision approach to enhance patient health and outcomes [3] Pipeline Development - Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, including ESK-001 for systemic immune-mediated disorders like moderate-to-severe plaque psoriasis and systemic lupus erythematosus [3] - A-005 is being developed for neuroinflammatory and neurodegenerative diseases [3] - The pipeline also features lonigutamab, an anti-insulin-like growth factor 1 receptor therapy for thyroid eye disease, along with several preclinical programs [3] Upcoming Events - Martin Babler, President and CEO of Alumis, will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 3:10 p.m. ET [1] - A live webcast of the presentation will be available on the Alumis website, with a replay archived for 90 days [2]

Core Insights - Alumis Inc. has completed patient enrollment in its pivotal Phase 3 ONWARD clinical program for ESK-001, targeting moderate-to-severe plaque psoriasis, with over 1,700 patients enrolled [2][4] - Topline results are expected to be reported in early Q1 2026, indicating progress towards providing new treatment options for patients [1][2] - ESK-001 is a next-generation oral TYK2 inhibitor designed to address immune dysregulation in various diseases, including plaque psoriasis [3][7] Clinical Program Details - The ONWARD clinical program consists of two parallel global Phase 3 trials, ONWARD1 and ONWARD2, each lasting 24 weeks and designed to evaluate the efficacy and safety of ESK-001 [4][5] - Patients are randomized in a 2:1:1 ratio to receive either ESK-001 40 mg twice daily, placebo, or apremilast, with co-primary endpoints focusing on the Psoriasis Area and Severity Index (PASI 75) and sPGA score [4][5] - An optional long-term extension trial, ONWARD3, is ongoing to assess the durability and long-term safety of ESK-001 for patients completing Week 24 [5] Product Profile - ESK-001 is characterized as a highly selective oral TYK2 inhibitor, aiming to minimize off-target effects while providing effective treatment for immune-mediated diseases [3][7] - The drug's development is supported by positive data from the Phase 2 STRIDE clinical trial and ongoing long-term open-label extensions [5] Broader Development Pipeline - Alumis is also exploring ESK-001's potential in other immune-mediated conditions, including a Phase 2b trial for systemic lupus erythematosus [6][7] - The company is developing a once-daily modified-release formulation of ESK-001 to enhance patient convenience compared to the current twice-daily regimen [5]

Company Overview - Alumis Inc. has completed its merger with ACELYRIN, Inc., establishing itself as a leading clinical-stage biopharma company with a differentiated portfolio of therapies and a strong balance sheet [1][3] - Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned, with ACELYRIN common stock ceasing to trade on NASDAQ [2] Financial Position - The merger significantly strengthens Alumis' balance sheet, allowing for the advancement of its late-stage portfolio and the development of transformative therapies for patients [3] - Alumis now has a cash runway that extends into 2027, supporting multiple planned key data readouts [3] Product Pipeline - Alumis is developing next-generation targeted therapies for immune-mediated diseases, including oral tyrosine kinase 2 inhibitors such as ESK-001 for systemic immune-mediated disorders and A-005 for neuroinflammatory diseases [5] - The pipeline also includes lonigutamab, an anti–insulin-like growth factor 1 receptor therapy for thyroid eye disease, along with several preclinical programs identified through a precision approach [5] Advisory Team - Morgan Stanley & Co. LLC served as the financial advisor to Alumis, while Cooley LLP acted as its legal counsel [4] - Guggenheim Securities, LLC served as the financial advisor to ACELYRIN, with Fenwick & West LLP and Paul Hastings LLP providing legal counsel [4]

Financial Performance - The company reported a net loss of $99.0 million for the three months ended March 31, 2025, compared to a net loss of $49.8 million for the same period in 2024, resulting in an accumulated deficit of $757.5 million as of March 31, 2025[215]. - Total revenue for the three months ended March 31, 2025, was $17.4 million, all from license revenue, compared to no revenue in the same period in 2024[251][252]. - The net loss for the three months ended March 31, 2025, was $99.0 million, a 99% increase from a net loss of $49.8 million in the same period in 2024[251]. - The net cash used in operating activities for the three months ended March 31, 2025, was $80.4 million, compared to $44.3 million for the same period in 2024, indicating a significant increase in operational losses[276][278]. - The company reported a net loss of $99.0 million for the three months ended March 31, 2025, which was partially offset by changes in operating assets and liabilities of $11.5 million and non-cash items totaling $7.1 million[277]. Research and Development - The company is developing two TYK2 inhibitors: ESK-001, which is in Phase 3 trials for plaque psoriasis, and A-005, which is in Phase 1 trials for CNS indications[212]. - The company has incurred significant operating losses primarily due to research and development costs, with fluctuations expected based on the timing of clinical trials and product candidate acquisitions[216]. - Research and development expenses increased by 130% to $96.6 million for the three months ended March 31, 2025, from $41.9 million in the same period in 2024[251][253]. - External research and development costs for ESK-001 were $66.5 million for the three months ended March 31, 2025, up from $24.7 million in the same period in 2024[260]. - Personnel-related costs in research and development increased by 94% to $17.7 million for the three months ended March 31, 2025, from $9.1 million in the same period in 2024[253][258]. - The company incurred a milestone payment of $23.0 million in August 2024 related to the first administration of ESK-001 in a Phase 3 clinical trial, recorded in research and development expenses[285]. Collaboration and Partnerships - The company has entered into a Collaboration Agreement with Kaken for the development and commercialization of ESK-001 in Japan, retaining rights for all other indications and geographies[232]. - Kaken made a non-refundable upfront payment of $20.0 million and will pay an additional $20.0 million towards global development costs of ESK-001 through the end of 2026[236]. Funding and Capital Requirements - The company anticipates significant increases in expenses related to ongoing clinical trials, potential mergers, and the establishment of commercialization capabilities[218]. - The company anticipates needing substantial additional funding to support ongoing research and development activities and maintain future operations[269]. - As of March 31, 2025, the company has cash, cash equivalents, and marketable securities totaling $208.7 million, which is insufficient to meet operating and capital requirements for at least the next 12 months[268]. - The company reported net cash provided by financing activities of $129.1 million for the three months ended March 31, 2024, primarily from the issuance of Series C redeemable convertible preferred stock[283]. Market and Economic Conditions - The company is subject to macroeconomic trends that could impact its operations, including rising inflation, interest rates, and geopolitical instability, although these have not yet materially affected its business[225]. - Inflation has not had a material effect on the company's business or financial condition[310]. - The company does not believe that a hypothetical 10% increase or decrease in interest rates would have a material effect on its financial statements[308]. Accounting and Financial Reporting - The company recognizes revenue based on the transfer of control over promised goods or services, either at a point in time or over time, with adjustments recorded on a cumulative catch-up basis[295]. - Accounts receivable are recorded when the right to consideration is deemed unconditional, while consideration that does not meet revenue recognition criteria is classified as deferred revenue[296]. - Stock-based compensation expense is measured using the Black-Scholes option-pricing model, with assumptions including common stock fair value and expected volatility, and is expensed over the requisite service period[297]. - The company is classified as an "emerging growth company" under the JOBS Act, allowing it to delay the adoption of certain accounting standards until they apply to private companies[303]. - As of June 30, 2024, the company qualifies as a "smaller reporting company," with a market value of common stock and non-voting common stock held by non-affiliates less than $700.0 million and annual revenue below $100.0 million[305]. Risks and Uncertainties - The company is subject to risks related to the development of new drug candidates, which may lead to unforeseen expenses and delays[269]. - Foreign currency transaction gains and losses have not been material, and the company does not have a formal hedging program for foreign currency[309].

First Quarter 2025 and Recent Highlights ● Updates related to merger agreement with ACELYRIN, Inc. (ACELYRIN), enabling enhanced value creation opportunities for each company's respective stockholders and positioning transaction for successful close in the second quarter of 2025 ● On May 13, 2025, Alumis stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN at its Special Meeting of Stockholders. ● In April 2025, Alumis and ACELYRIN agreed to ...